The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells
Authors:
- Seung Kwan LeeSLSeung Kwan Lee
- Kwang Sik SuhKSKwang Sik Suh
- Byung-Jo KimBKByung-Jo Kim
Open Access
- 31 October 2011
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 29 (2) , 169-177
Abstract
Osteoblastic bone formation and osteoclastic bone resorption are in balance to maintain a constant, homeostatically controlled amount of bone. Excessive bone resorption by osteoclasts is involved in the pathogenesis of bone-related disorders. In the present study, we evaluated the inhibitory effects of glabridin, a flavonoid purified from licorice root, on the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation and its molecular mechanisms in murine osteoclast progenitor RAW264.7 cells. Glabridin significantly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity, the formation of multinucleated osteoclasts and resorption-pit formation. In mechanistic studies of the anti-osteoclastogenic potential of glabridin, we found that glabridin inhibited RANKL-induced expression of c-Fos and subsequent expression of NFATc1, which is a master regulator of osteoclastogenesis. Interestingly, glabridin inhibited the RANKL-induced expression of signaling molecules (TRAF6, GAB2, ERK2, JNK1 and MKK7) and osteoclast survival-related signaling pathways such as c-Src, PI3K and Akt2. Glabridin also inhibited the bone resorptive activity of mature osteoclasts by inhibiting osteoclast-associated genes (cathepsin K, MMP-9, CAII, TCIRG1, OSTM1 and CLCN7). Taken together, our data suggest that glabridin holds great promise for use in preventing osteoclastogenesis by inhibiting RANKL-induced activation of signaling molecules and subsequent transcription factors in osteoclast precursors and these findings may be useful for evaluating treatment options in bone-destructive diseases.Keywords
This publication has 33 references indexed in Scilit:
- Glabridin protects osteoblastic MC3T3-E1 cells against antimycin A induced cytotoxicityChemico-Biological Interactions, 2011
- NFATc1: Functions in osteoclastsThe International Journal of Biochemistry & Cell Biology, 2010
- Advances in osteoclast biology resulting from the study of osteopetrotic mutationsHuman Genetics, 2008
- Osteoclast lineage and functionArchives of Biochemistry and Biophysics, 2008
- The licorice root derived isoflavan glabridin increases the function of osteoblastic MC3T3-E1 cellsBiochemical Pharmacology, 2005
- A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cellsBone, 2004
- Characterization of Osteoclasts from Patients Harboring a G215R Mutation in ClC-7 Causing Autosomal Dominant Osteopetrosis Type IIThe American Journal of Pathology, 2004
- Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of OsteoclastsDevelopmental Cell, 2002
- Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and ManCell, 2001
- Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial DysplasiaCell, 1997